lotis-9: loncastuximab tesirine and rituximab in unfit/frail patients with dlbcl
Published 1 year ago • 259 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
1:16
lotis-9 trial design: loncastuximab tesirine plus rituximab in elderly patients with dlbcl
-
1:09
loncastuximab tesirine: long-term survival data from lotis-2 & insights into the lotis-7 trial
-
4:45
lotis-5: loncastuximab tesirine rituximab for elderly patients with r/r dlbcl
-
1:37
loncastuximab tesirine as a consolidation strategy post-car t-cell therapy in dlbcl
-
2:27
loncastuximab tesirine plus rituximab in r/r follicular lymphoma
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
2:04
updated long-term follow-up of sequoia: zanubrutinib vs bendamustine-rituximab in untreated cll/sll
-
15:59
phylogenomic branch length estimation using... - yasamin tabatabaee - evolcompgen - ismb/eccb 2023
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
6:28
cytoquest™ cr ctc enrichment - rbc lysis
-
0:42
the limited access to novel therapeutics for sickle cell disease in lmics
-
2:45
swift-seq: single-cell rna sequencing of ctcs for patients with multiple myeloma and precursors
-
1:28
a long-term analysis of lenalidomide and rituximab for the treatment of cll
-
8:57
outcomes of sct in t-all and t-lbl
-
1:12
traverse: acalabrutinib venetoclax and rituximab for treatment-naïve mcl
-
1:01
pirtobrutinib, venetoclax, and rituximab in the treatment of r/r cll: insights from the bruin trial
-
0:53
biosimilar rituximab in the treatment of cll
-
1:43
e7820 in combination with venetoclax in patients with splicing factor mutant myeloid malignancies
-
2:08
the venice-1 trial: venetoclax monotherapy in r/r cll
-
1:26
prognostic and predictive biomarkers in cll and their potential in guiding treatment decisions
-
2:21
targeting b-cell receptor signaling with btk degraders to treat cll